Phase 1 success de-risks SCY-247's IV formulation; watch for FDA alignment on Phase 2 design and milestone triggers under the BARDA contract. The BARDA award significantly reduces dilution risk for a clinical-stage biotech.
Price Chart
Executive Summary
Scynexis announced positive Phase 1 topline results for IV SCY-247, showing good tolerability and target exposures at 50 mg+ doses. The company plans to initiate Phase 2 in 2027, supported by a BARDA contract providing up to ~$214 million in non-dilutive funding. This de-risks the program and extends cash runway into 2029.
Key Financial Metrics
Key Facts
- Phase 1 SAD/MAD trial of IV SCY-247 met safety and PK endpoints; no drug-related serious adverse events
- IV doses of 50 mg or higher achieved target exposures (AUC0–24 of 20 µg·h/mL) from murine efficacy models
- Company expects to initiate Phase 2 in 2027 for both oral and IV formulations, subject to FDA agreement
- BARDA contract (75A50126C00007) provides up to ~$214 million in non-dilutive funding if milestones achieved
- SCY-247 has Orphan Drug, QIDP, and Fast Track designations from FDA
- SCY-770 Phase 2 study on track for Q4 2026; cash runway into 2029 unchanged
Financial Impact
Up to ~$214 million in non-dilutive BARDA funding; cash runway extended into 2029
Risk Factors
- Phase 2 may not reach alignment with FDA on design or timelines
- BARDA may not exercise all options under the contract
- Clinical-stage company with no approved revenue from SCY-247; relies on existing cash and BARDA funding
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3386244 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $3.81 | awaiting T+5 | — | $3.80 (−0.26%) |
Oct 6, 2026 21d ago | Press Release | $4.84 $3.99 | ▼ −17.56% | ▼ −17.42% | $3.80 (−21.49%) |
Sep 28, 2026 29d ago | Press Release | $4.62 $5.03 | ▲ +8.87% | ▲ +7.67% | $3.80 (−17.75%) |
Sep 22, 2026 5w ago | 8-K | $4.86 $4.66 | ▼ −4.12% | ▼ −2.93% | $3.80 (−21.81%) |
Sep 10, 2026 6w ago | 8-K | $4.70 $4.45 | ▼ −5.32% | ▼ −4.82% | $3.80 (−19.15%) |
Jun 26, 2026 17w ago | 8-K | $3.87 $4.73 | ▲ +22.22% | ▲ +20.83% | $3.80 (−1.81%) |
May 22, 2026 22w ago | 8-K | $5.45 $5.33 | ▼ −2.17% | ▼ −3.25% | $3.80 (−30.25%) |
May 11, 2026 24w ago | Press Release | $6.24 $5.26 | ▲ +15.77% | ▲ +15.17% | $3.80 (+39.10%) |
Apr 20, 2026 27w ago | 8-K | $8.48 $7.89 | ▼ −6.98% | ▼ −8.06% | $3.80 (−55.19%) |
Mar 31, 2026 30w ago | Press Release | $7.34 $7.97 | ▲ +8.62% | ▲ +4.67% | $3.80 (−48.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers